Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

L. Gulácsi, Fanni Rencz, Márta Péntek, Valentin Brodszky, Ruth Lopert, Noémi V. Hevér, Petra Baji

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Several Central and Eastern European (CEE) countries require cost-utility analyses (CUAs) to support reimbursement formulary listing. However, CUAs informed by local evidence are often unavailable, and the cost-effectiveness of the several currently reimbursed biologicals is unclear. Aim: To estimate the cost-effectiveness as multiples of per capita GDP/quality adjusted life years (QALY) of four biologicals (infliximab, etanercept, adalimumab, golimumab) currently reimbursed in six CEE countries in six inflammatory rheumatoid and bowel disease conditions. Methods: Systematic literature review of published costutility analyses in the selected conditions, using the United Kingdom (UK) as reference country and with study selection criteria set to optimize the transfer of results to the CEEs. Prices in each CEE country were pro-rated against UK prices using purchasing power parity (PPP)-adjusted per capita GDP, and local GDP per capita/QALY ratios estimated. Results: Central and Eastern European countries list prices were 144-333% higher than pro rata prices. Out of 85 CUAs identified by previous systematic literature reviews, 15 were selected as a convenience sample for estimating the costeffectiveness of biologicals in the CEE countries in terms of per capita GDP/QALY. Per capita GDP/QALY values varied from 0.42 to 6.4 across countries and conditions (Bulgaria: 0.97-6.38; Czech Republic: 0.42-2.76; Hungary: 0.54-3.54; Poland:0.59-3.90;Romania: 0.77-5.07; Slovakia: 0.55-3.61). Conclusion: While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data.

Original languageEnglish
JournalEuropean Journal of Health Economics
Volume15
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2014

Fingerprint

Quality-Adjusted Life Years
Cost-Benefit Analysis
Formularies
Bulgaria
Romania
Slovakia
Hungary
Czech Republic
Poland
Parity
Inflammatory Bowel Diseases
Patient Selection
Cost-utility
Transferability
Central and Eastern European countries
Decision Making
Quality-adjusted life years
Per capita GDP
Costs and Cost Analysis
Cost-effectiveness

Keywords

  • Biologicals
  • Central and eastern europe
  • Cost-utility
  • HTA
  • Inflammatory conditions
  • Reimbursement

ASJC Scopus subject areas

  • Health Policy
  • Economics, Econometrics and Finance (miscellaneous)
  • Medicine(all)

Cite this

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. / Gulácsi, L.; Rencz, Fanni; Péntek, Márta; Brodszky, Valentin; Lopert, Ruth; Hevér, Noémi V.; Baji, Petra.

In: European Journal of Health Economics, Vol. 15, No. SUPPL. 1, 2014.

Research output: Contribution to journalArticle

Gulácsi, L. ; Rencz, Fanni ; Péntek, Márta ; Brodszky, Valentin ; Lopert, Ruth ; Hevér, Noémi V. ; Baji, Petra. / Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. In: European Journal of Health Economics. 2014 ; Vol. 15, No. SUPPL. 1.
@article{4783fbd381f54c05a2cd7ef60aa64b20,
title = "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries",
abstract = "Background: Several Central and Eastern European (CEE) countries require cost-utility analyses (CUAs) to support reimbursement formulary listing. However, CUAs informed by local evidence are often unavailable, and the cost-effectiveness of the several currently reimbursed biologicals is unclear. Aim: To estimate the cost-effectiveness as multiples of per capita GDP/quality adjusted life years (QALY) of four biologicals (infliximab, etanercept, adalimumab, golimumab) currently reimbursed in six CEE countries in six inflammatory rheumatoid and bowel disease conditions. Methods: Systematic literature review of published costutility analyses in the selected conditions, using the United Kingdom (UK) as reference country and with study selection criteria set to optimize the transfer of results to the CEEs. Prices in each CEE country were pro-rated against UK prices using purchasing power parity (PPP)-adjusted per capita GDP, and local GDP per capita/QALY ratios estimated. Results: Central and Eastern European countries list prices were 144-333{\%} higher than pro rata prices. Out of 85 CUAs identified by previous systematic literature reviews, 15 were selected as a convenience sample for estimating the costeffectiveness of biologicals in the CEE countries in terms of per capita GDP/QALY. Per capita GDP/QALY values varied from 0.42 to 6.4 across countries and conditions (Bulgaria: 0.97-6.38; Czech Republic: 0.42-2.76; Hungary: 0.54-3.54; Poland:0.59-3.90;Romania: 0.77-5.07; Slovakia: 0.55-3.61). Conclusion: While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data.",
keywords = "Biologicals, Central and eastern europe, Cost-utility, HTA, Inflammatory conditions, Reimbursement",
author = "L. Gul{\'a}csi and Fanni Rencz and M{\'a}rta P{\'e}ntek and Valentin Brodszky and Ruth Lopert and Hev{\'e}r, {No{\'e}mi V.} and Petra Baji",
year = "2014",
doi = "10.1007/s10198-014-0591-7",
language = "English",
volume = "15",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

AU - Gulácsi, L.

AU - Rencz, Fanni

AU - Péntek, Márta

AU - Brodszky, Valentin

AU - Lopert, Ruth

AU - Hevér, Noémi V.

AU - Baji, Petra

PY - 2014

Y1 - 2014

N2 - Background: Several Central and Eastern European (CEE) countries require cost-utility analyses (CUAs) to support reimbursement formulary listing. However, CUAs informed by local evidence are often unavailable, and the cost-effectiveness of the several currently reimbursed biologicals is unclear. Aim: To estimate the cost-effectiveness as multiples of per capita GDP/quality adjusted life years (QALY) of four biologicals (infliximab, etanercept, adalimumab, golimumab) currently reimbursed in six CEE countries in six inflammatory rheumatoid and bowel disease conditions. Methods: Systematic literature review of published costutility analyses in the selected conditions, using the United Kingdom (UK) as reference country and with study selection criteria set to optimize the transfer of results to the CEEs. Prices in each CEE country were pro-rated against UK prices using purchasing power parity (PPP)-adjusted per capita GDP, and local GDP per capita/QALY ratios estimated. Results: Central and Eastern European countries list prices were 144-333% higher than pro rata prices. Out of 85 CUAs identified by previous systematic literature reviews, 15 were selected as a convenience sample for estimating the costeffectiveness of biologicals in the CEE countries in terms of per capita GDP/QALY. Per capita GDP/QALY values varied from 0.42 to 6.4 across countries and conditions (Bulgaria: 0.97-6.38; Czech Republic: 0.42-2.76; Hungary: 0.54-3.54; Poland:0.59-3.90;Romania: 0.77-5.07; Slovakia: 0.55-3.61). Conclusion: While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data.

AB - Background: Several Central and Eastern European (CEE) countries require cost-utility analyses (CUAs) to support reimbursement formulary listing. However, CUAs informed by local evidence are often unavailable, and the cost-effectiveness of the several currently reimbursed biologicals is unclear. Aim: To estimate the cost-effectiveness as multiples of per capita GDP/quality adjusted life years (QALY) of four biologicals (infliximab, etanercept, adalimumab, golimumab) currently reimbursed in six CEE countries in six inflammatory rheumatoid and bowel disease conditions. Methods: Systematic literature review of published costutility analyses in the selected conditions, using the United Kingdom (UK) as reference country and with study selection criteria set to optimize the transfer of results to the CEEs. Prices in each CEE country were pro-rated against UK prices using purchasing power parity (PPP)-adjusted per capita GDP, and local GDP per capita/QALY ratios estimated. Results: Central and Eastern European countries list prices were 144-333% higher than pro rata prices. Out of 85 CUAs identified by previous systematic literature reviews, 15 were selected as a convenience sample for estimating the costeffectiveness of biologicals in the CEE countries in terms of per capita GDP/QALY. Per capita GDP/QALY values varied from 0.42 to 6.4 across countries and conditions (Bulgaria: 0.97-6.38; Czech Republic: 0.42-2.76; Hungary: 0.54-3.54; Poland:0.59-3.90;Romania: 0.77-5.07; Slovakia: 0.55-3.61). Conclusion: While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data.

KW - Biologicals

KW - Central and eastern europe

KW - Cost-utility

KW - HTA

KW - Inflammatory conditions

KW - Reimbursement

UR - http://www.scopus.com/inward/record.url?scp=84905719350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905719350&partnerID=8YFLogxK

U2 - 10.1007/s10198-014-0591-7

DO - 10.1007/s10198-014-0591-7

M3 - Article

C2 - 24832833

AN - SCOPUS:84905719350

VL - 15

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - SUPPL. 1

ER -